Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib + TKI in CML with MRD
NCT04216563Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of asciminib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2020; status: terminated.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04216563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216563.